AMAG Pharmaceuticals' (AMAG) Hold Rating Reaffirmed at Cowen and Company

Oceane Deschanel
Agosto 14, 2017

The value of the company's investment in AMAG Pharmaceuticals, Inc. decreased from $2,280,000 to $1,110,000 decreasing 51.3% since the last quarter.

Media coverage about AMAG Pharmaceuticals (NASDAQ:AMAG) has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports.

A number of other brokerages have also recently issued reports on AMAG. Cantor Fitzgerald reaffirmed a "hold" rating and issued a $23.00 target price on shares of AMAG Pharmaceuticals in a report on Tuesday, May 2nd.

Among 9 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 2 have Buy rating, 1 Sell and 6 Hold.

COPYRIGHT VIOLATION WARNING: "Somewhat Positive News Coverage Somewhat Unlikely to Impact AMAG Pharmaceuticals (AMAG) Share Price" was originally reported by Transcript Daily and is the sole property of of Transcript Daily. Finally, BidaskClub upgraded shares of AMAG Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, July 6th. Zacks Investment Research raised AMAG Pharmaceuticals from a "hold" rating to a "buy" rating and set a $22.00 target price for the company in a report on Tuesday, July 11th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the company's stock. Dupont Cap Mgmt Corporation holds 0.03% in AMAG Pharmaceuticals, Inc.

Unilever plc (ULVR) Insider Mary Ma Buys 460 Shares
Spears Abacus Advisors LLC acquired a new stake in Unilever NV during the second quarter valued at approximately $202,000. TRADEMARK VIOLATION WARNING: This news story was published by StockNewsTimes and is owned by of StockNewsTimes.

Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 17.10 on Monday. The company had a trading volume of 1,028,289 shares. The company has market cap of $591.08 million. The company has a 50-day moving average price of $19.06 and a 200 day moving average price of $20.82. AMAG Pharmaceuticals has a 12 month low of $16.00 and a 12 month high of $36.83.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The firm had revenue of $158.39 million for the quarter, compared to analysts' expectations of $158.83 million. Equities research analysts anticipate that AMAG Pharmaceuticals, Inc. will post ($1.37) EPS for the current year. The company's quarterly revenue was up 24.3% compared to the same quarter previous year. Next quarter's EPS is forecasted at $0.29 with next year's EPS projected to be $-1.60.

AMAG Pharmaceuticals, Inc.is a pharmaceutical company. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of US and global trademark and copyright laws. The original version of this piece can be accessed at https://weekherald.com/2017/08/13/cowen-and-company-reaffirms-hold-rating-for-amag-pharmaceuticals-inc-amag.html. "Globenewswire.com's news article titled: "AMAG Pharmaceuticals Launches Intrarosaâ"¢ (prasterone) in the U.S. â€" a Novel ..." with publication date: "July 24, 2017 was also an interesting one. It increased, as 20 investors sold AMAG shares while 53 reduced holdings. Following the completion of the transaction, the senior vice president now owns 28,336 shares in the company, valued at approximately $566,720. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

A number of hedge funds have recently modified their holdings of AMAG. As of the end of the quarter Tiaa Cref Investment Management LLC had acquired 49,209 shares growing its stake by 39.7%. Vanguard Group Inc. now owns 3,085,348 shares of the specialty pharmaceutical company's stock worth $69,576,000 after buying an additional 176,832 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of AMAG Pharmaceuticals by 1.7% in the second quarter. Municipal Employees Retirement System of MI now owns 8,280 shares of the specialty pharmaceutical company's stock worth $152,000 after buying an additional 510 shares during the period. Municipal Employees Retirement System of MI raised its position in shares of AMAG Pharmaceuticals by 6.6% in the second quarter. Louisiana State Employees Retirement System now owns 14,000 shares of the specialty pharmaceutical company's stock valued at $316,000 after buying an additional 200 shares during the period. Nordea Investment Management AB boosted its position in AMAG Pharmaceuticals by 1.1% in the second quarter. Arizona State Retirement System now owns 17,900 shares of the specialty pharmaceutical company's stock valued at $404,000 after buying an additional 300 shares during the period. As of quarter end Nationwide Fund Advisors had acquired 5,800 shares growing its position 12.4%. Acadian Asset Management LLC now owns 1,226,690 shares of the specialty pharmaceutical company's stock worth $27,659,000 after buying an additional 1,086,937 shares during the last quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company.

Outros relatórios LazerEsportes

Discuta este artigo

SIGA O NOSSO JORNAL